ETON Eton Pharmaceuticals
Price Chart
Executive Summary
Eton Pharmaceuticals has dosed the first patient in a pilot clinical study evaluating ET-700, its extended-release zinc acetate formulation for Wilson disease. Topline results are expected in H2 2026, with a pivotal trial planned for early 2027 if data are positive. The company projects peak U.S. sales could exceed $100 million if approved.
Actionable Insight
Monitor topline data from the pilot study in H2 2026 as a key catalyst — positive results could support advancement to pivotal trials and re-rate the stock. Given the early stage and use of healthy volunteers, interpret results cautiously regarding clinical efficacy in patients.
Key Facts
- First patient dosed in a pilot clinical trial for ET-700, an extended-release zinc acetate for Wilson disease.
- Study is a double-blinded, placebo-controlled trial in 36 healthy volunteers across three arms, using 64Cu PET imaging to assess intestinal copper absorption.
- Topline results expected in second half of 2026; pivotal study could begin in early 2027 if results are positive.
- ET-700 is being tested as a twice-daily formulation versus standard-of-care Galzin (zinc acetate) three times daily.
- Company projects ET-700 could achieve over $100 million in peak annual U.S. sales if approved.
Financial Impact
Potential peak sales >$100M in the U.S. if ET-700 is approved; no near-term revenue impact expected.
Risk Factors
- Pilot study uses healthy volunteers, not Wilson disease patients, limiting direct clinical applicability.
- Failure to demonstrate reduced copper absorption or safety issues could halt development.
- Market opportunity depends on adoption over existing generics and adherence to dosing regimen.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281436 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
11d ago
|
Insider Cluster
| $28.68 $29.13 | ▼ −1.57% | ▼ −4.32% | $29.95 (−4.43%) |
|
May 28, 2026
12d ago
|
144
| $31.86 $27.61 | ▲ +13.34% | ▲ +13.29% | $29.95 (+5.99%) |
|
May 19, 2026
21d ago
|
8-K
| $34.45 $32.40 | ▼ −5.95% | ▼ −7.19% | $29.95 (−13.06%) |
|
Apr 27, 2026
6w ago
|
8-K
| $23.45 $30.16 | ▲ +28.61% | ▲ +28.21% | $29.95 (+27.72%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $23.45 $30.16 | ▲ +28.61% | ▲ +28.21% | $29.95 (+27.72%) |
|
Apr 16, 2026
7w ago
|
8-K
| $24.43 $22.97 | ▼ −5.98% | ▼ −6.96% | $29.95 (+22.60%) |
|
Apr 15, 2026
7w ago
|
8-K
| $24.43 $22.97 | ▼ −5.98% | ▼ −6.96% | $29.95 (+22.60%) |
|
Mar 3, 2026
14w ago
|
Press Release
| $17.53 $18.09 | ▲ +3.19% | ▲ +4.53% | $29.95 (+70.85%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $18.15 $16.70 | ▼ −7.99% | ▼ −6.78% | $29.95 (+65.01%) |
|
Feb 28, 2026
14w ago
|
Institutional Cluster
| $18.15 $16.70 | ▼ −7.99% | ▼ −6.78% | $29.95 (+65.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access